Multicenter Cohort Analysis of Anoikis and EMT: Implications for Prognosis and Therapy in Lung Adenocarcinoma

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Sep 19

PMID 39298078

Authors

Lu Yin

Zhanshuo Zhang

Zhu Yan

Qiuyue Yan

Affiliations

Soon will be listed here.

Abstract

Background: Anoikis and epithelial-mesenchymal transition (EMT) are pivotal in the distant metastasis of lung adenocarcinoma (LUAD). A detailed understanding of their interplay and the identification of key genes is vital for effective therapeutic strategies against LUAD metastasis.

Methods: Key prognostic genes related to anoikis and EMT were identified through univariate Cox regression analysis. We utilized ten machine learning algorithms to develop the Anoikis and EMT-Related Optimal Model (AEOM). The TCGA-LUAD dataset served as the training cohort, while six additional international multicenter LUAD datasets were employed as validation cohorts. The average concordance index (c-index) was used to evaluate model performance and identify the most effective model. Subsequent multi-omics analyses were conducted to explore differences in pathway enrichment, immune infiltration, and mutation landscapes between high and low AEOM groups. Experimental validation demonstrated that RHPN2, a key biomarker within the model, acts as an oncogene facilitating LUAD progression.

Results: The AEOM displayed superior prognostic predictive performance for LUAD patients, outperforming numerous previously published LUAD signatures. Biologically, the AEOM was notably associated with immune features; the high AEOM group exhibited decreased immune activity and a tendency towards immune-cold tumors, as well as a higher tumor mutational burden (TMB). Subgroup analysis revealed that the low AEOM + high TMB group had the most favorable prognosis. The high AEOM group was primarily enriched in cell cycle-related pathways, promoting cancer cell proliferation. RHPN2, a crucial gene within the AEOM (correlation = 0.85, P < 0.05), was linked to poorer prognosis in LUAD patients with elevated RHPN2 expression. Further in vitro experiments showed that RHPN2 modulates LUAD cell proliferation and invasion.

Conclusion: The AEOM provides a robust prognostic model for LUAD, uncovering critical immune and biological pathways, with RHPN2 identified as a key oncogenic driver. These findings offer valuable insights for targeted therapies and enhanced patient outcomes.

References

Hu J, Yu A, Othmane B, Qiu D, Li H, Li C . Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 2021; 11(7):3089-3108. PMC: 7847675. DOI: 10.7150/thno.53649. View

Kang Y, Jin Y, Li Q, Yuan X . Advances in Lung Cancer Driver Genes Associated With Brain Metastasis. Front Oncol. 2021; 10:606300. PMC: 7848146. DOI: 10.3389/fonc.2020.606300. View

Zhao X, Wang Z, Tang Z, Hu J, Zhou Y, Ge J . An anoikis-related gene signature for prediction of the prognosis in prostate cancer. Front Oncol. 2023; 13:1169425. PMC: 10469923. DOI: 10.3389/fonc.2023.1169425. View

Rousseaux S, Debernardi A, Jacquiau B, Vitte A, Vesin A, Nagy-Mignotte H . Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013; 5(186):186ra66. PMC: 4818008. DOI: 10.1126/scitranslmed.3005723. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Li Y, Yan B, He S . Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 2023; 169:115891. DOI: 10.1016/j.biopha.2023.115891. View

Manfioletti G, Fedele M . Epithelial-Mesenchymal Transition (EMT) 2021. Int J Mol Sci. 2022; 23(10). PMC: 9145979. DOI: 10.3390/ijms23105848. View

Xu L, Deng C, Pang B, Zhang X, Liu W, Liao G . TIP: A Web Server for Resolving Tumor Immunophenotype Profiling. Cancer Res. 2018; 78(23):6575-6580. DOI: 10.1158/0008-5472.CAN-18-0689. View

Zhang P, Dong S, Sun W, Zhong W, Xiong J, Gong X . Deciphering Treg cell roles in esophageal squamous cell carcinoma: a comprehensive prognostic and immunotherapeutic analysis. Front Mol Biosci. 2023; 10:1277530. PMC: 10568469. DOI: 10.3389/fmolb.2023.1277530. View

10.

Wilkerson M, Yin X, Walter V, Zhao N, Cabanski C, Hayward M . Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One. 2012; 7(5):e36530. PMC: 3349715. DOI: 10.1371/journal.pone.0036530. View

11.

Cao R, Yuan L, Ma B, Wang G, Qiu W, Tian Y . An EMT-related gene signature for the prognosis of human bladder cancer. J Cell Mol Med. 2019; 24(1):605-617. PMC: 6933372. DOI: 10.1111/jcmm.14767. View

12.

Zhang P, Pei S, Zhou G, Zhang M, Zhang L, Zhang Z . Purine metabolism in lung adenocarcinoma: A single-cell analysis revealing prognostic and immunotherapeutic insights. J Cell Mol Med. 2024; 28(8):e18284. PMC: 11005461. DOI: 10.1111/jcmm.18284. View

13.

Zhou J, Yang S, Zhu D, Li H, Miao X, Gu M . The crosstalk between anoikis and epithelial-mesenchymal transition and their synergistic roles in predicting prognosis in colon adenocarcinoma. Front Oncol. 2023; 13:1184215. PMC: 10284081. DOI: 10.3389/fonc.2023.1184215. View

14.

Zhang L, Cui Y, Mei J, Zhang Z, Zhang P . Exploring cellular diversity in lung adenocarcinoma epithelium: Advancing prognostic methods and immunotherapeutic strategies. Cell Prolif. 2024; 57(11):e13703. PMC: 11533061. DOI: 10.1111/cpr.13703. View

15.

Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T . Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol. 2009; 27(17):2793-9. DOI: 10.1200/JCO.2008.19.7053. View

16.

Zhang P, Wu X, Wang D, Zhang M, Zhang B, Zhang Z . Unraveling the role of low-density lipoprotein-related genes in lung adenocarcinoma: Insights into tumor microenvironment and clinical prognosis. Environ Toxicol. 2024; 39(10):4479-4495. DOI: 10.1002/tox.24230. View

17.

Wang J, Luo Z, Lin L, Sui X, Yu L, Xu C . Anoikis-Associated Lung Cancer Metastasis: Mechanisms and Therapies. Cancers (Basel). 2022; 14(19). PMC: 9564242. DOI: 10.3390/cancers14194791. View

18.

Kim Y, Koo K, Sung J, Yun U, Kim H . Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol. 2012; 2012:306879. PMC: 3296207. DOI: 10.1155/2012/306879. View

19.

Dai Y, Zhang X, Ou Y, Zou L, Zhang D, Yang Q . Anoikis resistance--protagonists of breast cancer cells survive and metastasize after ECM detachment. Cell Commun Signal. 2023; 21(1):190. PMC: 10399053. DOI: 10.1186/s12964-023-01183-4. View

20.

Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R . Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2011; 72(1):100-11. DOI: 10.1158/0008-5472.CAN-11-1403. View